SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ISIS PHARMACEUTICALS
(NQNM:ISIS Last Sale: 31.1 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ISIS : $31.1)
$3,017 million Market Cap at September 12, 2013
Employs 300.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
1896 Rutherford Road Research Report Earnings Snapshot - Last 11/07/18
Carlsbad, CA 92008 Fact Sheet
Phone: (760) 931-9200 Financial Statements
Fax: (760) 931-9639 Peer Comparison
Annual Reports

Stanley T. Crooke, Chmn./Pres./CEO, B. Lynne Parshall, EVP/CFO
Focus is the discovery and development of a new class of drugs, antisense oligonucleotides, which may form a new basis for therapeutic drugs. Launched a joint venture with ALNYLAM PHARMACEUTICALS INC (ALNY), Regulus Therapeutics LLC, to develop microRNA therapies, September 7, 2007. Received $26.5 million from licensee ALNYLAM under their strategic relationship after ALNY signed a $1 billion deal with ROCHE July 9, 2007. ALNY stated "Isis technology and intellectual property have proven to be critical in creating siRNAs with drug-like properties." Isis owns or controls over 1,500 issued patents pertaining to nucleic acid based therapeutics. These patents were exclusively licensed to Alnylam for double-stranded RNAi therapeutics in 2004.
Historical Charts    Technical Analysis
No Historical Data available for ISIS

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ISIS $31.1 $ 0 $30.95 $31.555 631,704 $7.555 $34.31 97,002
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $3,016,762

A1821
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex